2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 6, 2017

2:30PM-4:00PM: Abstract Number: 1833

iRhom2 Deficiency Protects Fcgr2b-/- Lupus-Prone Mice from Kidney Damage By Modulating ADAM17-Dependent Shedding of TNF-α and EGFR Ligand

Systemic Lupus Erythematosus – Animal Models

2:30PM-4:00PM: Abstract Number: 1809

Lack of Placental Transfer of Certolizumab Pegol during Pregnancy: Results from a Prospective, Postmarketing, Multicenter, Pharmacokinetic Study

Reproductive Issues in Rheumatic Disorders

2:30PM-4:00PM: Abstract Number: 1808

Long-Term Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine in Patients with Systemic Lupus Erythematosus

Reproductive Issues in Rheumatic Disorders

2:30PM-4:00PM: Abstract Number: 1811

Lupus Patients, and Their Sisters, Have Higher Miscarriage Rates Than Healthy Women

Reproductive Issues in Rheumatic Disorders

2:30PM-4:00PM: Abstract Number: 1823

Methotrexate Requires High Serum BAFF Levels to Prevent Immunization Against TNF-α Inhibitors

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy I: Outcomes Therapy

2:30PM-4:00PM: Abstract Number: 1835

Microglial Defects Contribute to Neuropsychiatric Symptoms of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Animal Models

2:30PM-4:00PM: Abstract Number: 1848

NMR-Based Serum Metabolomics of Patients with Takayasu Arteritis (TA) and Relationship with Disease Activity

Vasculitis II: Biomarkers and Disease Activity

2:30PM-4:00PM: Abstract Number: 1794

Overexpression of Interleuk-22 Induces Expression of the Negative Immune-Regulator SOCS3 and Potently Reduces Collagen-Induced Arthritis in Mice

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis: Unexpected Effects from "Well-Known" Molecules

2:30PM-4:00PM: Abstract Number: 1804

Patient-Reported Outcomes and Damage Predict Mortality in Lupus

Patient Outcomes, Preferences, and Attitudes I

2:30PM-4:00PM: Abstract Number: 1829

Patterns and Predictors of Progression of Sacroiliitis in Psoriatic Arthritis and Its Relationship with Human Leukocyte Antigen (HLA) Alleles. Results from the Toronto Cohort

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment II

2:30PM-4:00PM: Abstract Number: 1815

Patterns of Methotrexate Use and Discontinuation in a U.S. Rheumatoid Arthritis Registry

Rheumatoid Arthritis – Clinical Aspects II: Treatment Patterns

2:30PM-4:00PM: Abstract Number: 1806

Performance of the Brief Index of Lupus Damage (BILD) in a Multi-Ethnic Population-Based Systemic Lupus Erythematosus (SLE) Cohort

Patient Outcomes, Preferences, and Attitudes I

2:30PM-4:00PM: Abstract Number: 1812

Preeclampsia and Incident Cardiovascular Disease in SLE Pregnancy

Reproductive Issues in Rheumatic Disorders

2:30PM-4:00PM: Abstract Number: 1807

Psychometric Evaluation of the Arthritis Research UK Musculoskeletal Health Questionnaire (MSK-HQ) in Inflammatory Arthritis

Patient Outcomes, Preferences, and Attitudes I

2:30PM-4:00PM: Abstract Number: 1801

Quantifying Clinical and Economic Outcomes Associated with Chronic Corticosteroid Exposure in a US Population

Measures and Measurement of Healthcare Quality

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].